Incumplimiento de la Ley de Eroom
Incumplimiento de la Ley de Eroom
“In solving a problem of this sort, the grand thing is to be able to reason backwards. That is a very useful accomplishment, and a very easy one, but people do not practise it much. In the every-day affairs of life it is more useful to reason forwards, and so the other comes to be neglected.” Sherlock Holmes, A Study in Scarlet
Incumplimiento de la Ley de Eroom
Between October 2014 and July 2025, a group of ~500 Ambrose Cell Therapy patients (including our predecessor group) broke the law, “Eroom’s Law.” [1] More on Eroom in a moment. First, what does Sherlock Holmes and backward reasoning have to do with proposing exponential improvements in safety, effectiveness, and the cost of healthcare?
Contrary to conventional and AI-driven drug development, we employed Sherlockian backward-reasoning to develop an adipose-derived regenerative cell (ADRC) platform therapy for rare genetic disorders. Counter-intuitively, our predecessor group pioneered our safe, experimental program with prevalent complex diseases such as congestive heart failure (CHF).
“Before my stem cell therapy in October 2014, I was told to prepare for hospice. I was only 71, but I had been admitting to the hospital every three months with heart failure.
Since my stem cells, I have only had one cardiac-related ER visit – for a brief Afib episode in 2024. Stem cells (ADRCs) saved my life,” extolled Patsy on her 81st birthday. – Patsy- Class IV congestive heart failure[2]
Compared to the $1.3 million lifetime cost of a heart transplant or the $130,000 per year cost of Class IV heart failure care, Patsy’s dramatic improvement from a single ADRC-based therapy signified that a new era of healthcare had begun.
Ambrose Patient-Reported Outcomes demonstrate a consistent pattern of sustained benefits while significantly reducing the cost of healthcare.
Moore’s Law
In 1965, Gordon Moore, Co-Founder of Intel Corp, observed that the number of transistors in a computer chip had doubled yearly. Moore’s Law evolved into the principle that the speed and capability of computers would double every two years.
With AI, computing power continues its exponential growth. As a result, the Information Age evolved backward from mainframes to minis to PCs to handhelds to wearables and implantables.
Eroom’s Law
Making a mockery of Big Pharma, Dr. Jack Scannell and colleagues spelled “Moore’s” backward, i.e., Eroom’s Law. (Nature Review Drug Discovery 2012). Here, they point out that drug discovery efficiency and efficacy experienced an exponential decades-long decline.
“Yet the number of new drugs approved per billion US dollars spent on R&D has halved roughly every 9 years since 1950, falling around 80-fold in inflation-adjusted terms.”[3]
An 80x decline represents a 98.75% decrease in cost-risk-benefit.
Reversing Eroom’s Law
Following the example set by Moore’s Law, we reviewed Ambrose’s follow-up data on dozens of patients who had suffered from diverse chronic conditions. We concluded that Eroom’s law is far from set in stone.
Rhonda’s three-year outcome embodies the potential for an Ambrose’s Law for healthcare.
“When I was 60, I had a major cerebral aneurysm. I spent two months in the ICU and was in and out of the hospital for the next eight months.
Before Ambrose, I took gabapentin, pain meds, and was calling 911 nearly every week with chronic back pain and sciatica. I took five blood pressure meds and used two inhalers for COPD-induced asthma. I watched TV with the volume at 72, not because I couldn’t hear it, but because I couldn’t remember what was being said.
Since (Ambrose) stem cells, I walk, garden, cook for my family and friends on holidays, and take care of my grandchildren. My cardiologist says I am a medical miracle, and my neurologist tested me and said my memory is” 99%”. Thank God for stem cells.”
Rhonda – 70 years old.
Ambrose’s Law
Ambrose’s Law states that the Protocolo maestro Ambrose spurs exponential growth in safety, effectiveness, and economic value for patients living with complex chronic conditions.
Ambrose’s Law requires backward reasoning from different directions. To accomplish exponential growth in healthcare outcomes and economics, we:
- provide Ambrose Cell Therapy as a service instead of putting a drug in a vial
- process ADRCs at the point of care instead of requiring a manufacturing plant
- price our one-time cell therapy priced at <10% of the lifetime cost of conventional care and less than 5% of the all-in cost of gene therapies
- target a 90% positive response rate with durable benefits and no cell-related adverse events.
Pharma’s Immutable Irrelevance
Ten years after Scannell’s scathing criticism of drug development, J Howick et al. (2022) doubled down on the risk and lack of reward of commonly prescribed drugs. “In this large sample of 1567 interventions studied within Cochrane reviews, only 5.6% were supported by high-quality evidence. Potential harms of healthcare interventions were measured more rarely than benefits.” [4]
Unimaginably, in 2025, Deloitte observed that the cost of a new drug approval increased from $1.3 billion to $2.2 billion since Scannell published Eroom’s Law.[5] Between Scannell, Howick, and Deloitte’s findings, this brings the fall to around 160 times.
In other words, since 1950, the net value of new drugs, biologics, and cell and gene therapies has approximated a bagel hole.
Rare Reasoning
Our backward reasoning leads to seeking FDA approval for an ADRC-based therapy for a rare genetic disorder and expanding from there.
- Beginning in 2007, prestigious medical research centers, including the University of Tokyo, Erasmus University, Texas Heart Institute, and Cedars-Sinai, conducted 71 clinical trials or experimental cases in which they treated 1,471 patients with Celution®-processed ADRCs.
- Over 10 years, Ambrose (and our predecessor group) treated over 500 no-option patients with heart failure, dementia, Parkinson’s disease, Crohn’s disease, or other prevalent conditions.
- Over that same 10-year period, Ambrose provided ~40 patients living with rare diseases the right to try their ADRCs—approximately 90% of those patients reported life-changing benefits despite their genetic mutations.[6]
- Ehlers-Danlos Syndrome =25
- Nail-Patella Syndrome =1
- Marfan Syndrome =3
- Rett Syndrome =1
- Dysgenesis of the Corpus Callosum =1
- Primary hemochromatosis =1
- Sickle cell thalassemia =1
- Rasmussen’s encephalitis with refractory seizures =1
- Synovial chondromatosis =1
- Post-cortical atrophy Alzheimer’s =1
- Multiple system atrophy – C =2
- Frontal temporal dementia =2
Our bold approach defies the forward-reasoning drug discovery dogma. Instead, we follow those who developed In Vitro Fertilization (IVF) for infertility and bone marrow transplants for blood cancers outside of formal FDA-approved trials.
Cracking the Genetic Disorder Code
Just as Holmes deciphered a family riddle in “The Musgrave Ritual” (1893),
Ambrose cracked the cellular codes for Emilie, who lived with sickle cell thalassemia and Marfan Syndrome, a connective tissue disease.
Emilie’s Reversal
After suffering from severe sickle cell thalassemia for seven years, in August 2023, Emilie flew from London to Los Angeles to exercise her Right to Try Ambrose Cell Therapy. Since Emilie’s one-time Ambrose treatment, she has not had a single severe sickle crisis.[7]
“Before Ambrose, I admitted to the A&E (accident and emergency department) with a severe sickle cell crisis nearly every week. I went from being very sick, then after my (Ambrose) treatment, my body went into healing mode. I realized a couple of days ago that the healing phase feels like it’s over.
I feel different. It’s more stable. It’s moved: next stage, next stage, and next stage.
Lili, my oldest daughter, treated me to a spa day for my (42nd) birthday. I swam in the pool for 40 minutes.
I couldn’t do that before because the cold water caused pain. I slept great. I had never gone swimming with my daughter. She’s 22.
It really, really, really is incredible. Having had this realization, I feel better spiritually.”
Saving Money While Saving a Life
In just the past two years, Emilie’s ADRCs would have saved the US healthcare system $135,000.
“Compared to matched controls, patients with SCD with recurrent VOCs (vaso-occlusive crises)* had significantly higher annual ($67,282 vs. $4134) and lifetime ($3.8 million vs. $229,000 over 50 years) healthcare costs, highlighting the need for cost-effective therapies that reduce clinical complications in this patient population“. (C Udeze et al. 2023)[8]
* A vaso-occlusive crisis (VOC), or sickle cell crisis, occurs when sickled red blood cells block small blood vessels. The restricted blood flow to tissues and organs causes severe pain.
However, that understates her long-term benefits and the cost savings to the system by an unfathomable amount. In February of 2023, Emilie had gotten her affairs in order and told her three children goodbye.
She was only 39 at the time, but Emilie didn’t believe she would make it to her 40th birthday, much less 50, the lifespan of the average person living with severe sickle cell disease.
Eroome’s Law Strikes Gene Therapy
In comparison to Emilie’s one-time cost of ~$50,000, the two FDA-approved sickle cell gene therapies, Casgevy (Vertex, Inc.) and Lyfgenia (blue bird bio, Inc.), have wholesale costs of $2,100,000 and $3,000,000 (with a guarantee), respectively. But the costs don’t end there—medical visits, the hospital costs for preconditioning with chemo and the treatment, and then the post-chemo related side effects, including infertility, pile on $100s of thousands more.
Sparse patient uptake led to blue bird bio, Inc. being “taken under” for $30 million by Carlyle. Investors once valued the Company at over $10 billion. Eroom’s Law strikes again.
The Connective Tissue Issue
Ambrose’s Law took hold when an increasing number of patients living with rare connective tissue diseases accessed their ADRCs under the Right to Try Act of 2017. Specifically, Ambrose patients living with Ehlers-Danlos Syndrome (EDS), Nail-Patella Syndrome (NPS), and Marfan Syndrome declared exponential improvements while lowering their ongoing costs of care, just as the doubling of transistors in a microchip had done for computing, thanks to Gordon Moore.
Most surprisingly, patients living with ultra-rare EDS variants – those observed in less than one in a million people – super-responded. From the odds angle, ADRCs reversed the odds of little or no response from one in a million to approximately nine-in-ten in ten reporting life-changing benefits.
“The most important thing is that I truly am better; whatever was causing my physical decline is no longer there. It is amazing.
Thank you for all your help and for all you are doing to get this regenerative therapy program into broad use.” Anna – 60 years old, Arthrochalasia EDS
“You’re bringing healing solutions to people who felt helpless and hopeless. You’re helping them to live outside of a body-centric existence. I’m so proud of you.” – Sally – 48 years old, Spondylodysplastic type I EDS
“I was an invalid. I am slowly getting better. I am sleeping 6-8 hours at a time, instead of waking up every two hours in pain, I am off all meds and able to walk with a cane.” – Melissa, 80 years Old, Ehlers-Danlos Syndrome, Dermatosparaxis Type
The remarkable Ambrose patient-reported outcomes of ~25 patients living with Ehlers-Danlos Syndrome, Marfan Syndrome, Nail Patella Syndrome, and ~10 other rare genetic disorders inspired our audacious vision.[9] (For more information, A Golden Era of ADRC-Therapy for Rare Connective Tissue Disorders is available upon request. contact@ambrosecelltherapy.com )
Moore’s Law Shortfall
While high-tech moguls like Jeff Bezos, Mark Zuckerberg, and Sergey Brin have leveraged Moore’s Law to flaunt their superyachts, Gen X, Millennials, Gen Z, and Gen Y come down with more chronic diseases at younger ages with each succeeding generation. Thus, Eroom’s Law impacts all of our lives.
Backwards Business Model Reasoning
“The opposite of a good idea is another good idea.” Rory Sutherland, Vice-Chairman, Ogilvy UK
Profits before patients has been a good idea for big pharma shareholders. In 2024, Eli Lilly, AbbVie, Johnson & Johnson, and seven other mega-cap drug companies reported over $100 billion in profits with near-zero paid in US taxes.
In comparison, patients pay an average of 25% of their income in federal, state, and local taxes. To add insult to injury, our tax dollars fund the payors, i.e., Medicare, Medicaid, and private insurance companies. Then the payors overpay big pharma for overpriced meds that don’t work very well.
Patients Before Profits
Our opposite good idea puts patients before profits. We propose pricing our one-time cell therapy at less than 5% of the lifetime costs of rare disease drugs and gene therapies. To be clear, Ambrose aims to make a profit, but in exchange for creating value for patients, their families, and society.
Moore’s Law created trillions of dollars of shareholder value, but Mr. Moore’s dream that computing power could exponentially change the world for the better fell short. Boldly, we postulate that Ambrose’s Law will catalyze a safe and effective healthcare ecosystem, vanquish Eroom’s Law, and change the world in tribute to Gordon Moore.
[1] Based on patient-reported outcomes, physician, and family reports.
[2] Patient Quotes are edited for clarity and brevity. Pseudonyms are used for patient privacy when requested.
[3] Scannell et al. Diagnosing the decline in pharmaceutical R&D efficiency Nature Review/Drug Discovery Vol 11 March 2012 191
[4] Howick, Jeremy et al. “Most healthcare interventions tested in Cochrane Reviews are not effective according to high quality evidence: a systematic review and meta-analysis.” Journal of clinical epidemiology vol. 148 (2022): 160-169.
[5] Terry C & Dondarski K. Deloitte Be brave, Be bold Measuring the return from pharmaceutical innovation 15th edition March 2025
[6] Based on patient-reported data believe to be reliable
[7] A Golden Era of ADRC-Based Therapy for Genetic Disorders – available upon request contact@ambrosecelltherapy.com
[8] Udeze, Chuka et al. “Economic and Clinical Burden of Managing Sickle Cell Disease with Recurrent Vaso-Occlusive Crises in the United States.” Advances in therapy vol. 40,8 (2023): 3543-3558.
[9] Based on patient and caregiver-reported data believed to be reliable
Sin embargo, las farmacéuticas y las biotecnológicas se centran en su modelo invariable de un fármaco, una enfermedad (o síntoma). La diversidad de causas y síntomas del TEA hace que este enfoque sea inviable. Además, los fármacos prescritos a menudo vienen con advertencias de caja negra, una multitud de posibles efectos secundarios e interacciones impredecibles. 
"A mis ojos y oídos, el órgano es el rey de los instrumentos".
En 2001, investigadores de la UCLA y de la Universidad de Pittsburgh descubrieron una reserva de células multipotentes en el tejido adiposo.
El tejido adiposo como tercer cerebro (Chaldakov et al. 2009) conecta el secretoma del tejido adiposo con la armonía neuroquímica, del SNA y multisistémica.
En octubre de 2021, Mary Grace, una aventurera de 58 años, se traumatizó de nuevo la rodilla izquierda haciendo senderismo por el Himalaya. Hasta entonces, había superado una conmoción cerebral hospitalaria, lesiones deportivas, dolor constante, niebla cerebral y fatiga crónica para escalar nuevas alturas. Pero este incidente fue diferente: una ambulancia aérea la bajó de la montaña.
Durante los 24 meses siguientes a su solo Tras el tratamiento con Ambrose, Mary Grace volvió a practicar senderismo, esquí y natación en aguas abiertas en México, nada menos que a contracorriente. También practicó windsurf junto a las ballenas.
Mary Grace debería haber sido un pilar de la salud al acercarse a los sesenta años, un punto crucial en la esperanza de vida. Sin embargo, su afición a los deportes exigentes provocó síndrome de sobreentrenamiento (OTS).
Nervio Vago
En contraste con la recuperación casi sin dolor de Mary Grace, Tiger Woods personifica los riesgos de un entrenamiento excesivo y de depender de cirugías, seguidas de medicamentos, para controlar su dolor y depresión.
Aunque Mary Grace no es una atleta de competición de talla mundial, la comparación es válida. Pocas mujeres han viajado a tantos lugares y de tantas maneras como ella.
“People often ask if stem cells work. Of course, they work. We are all walking stem cell products – the sperm, and the egg,” the revered James Willerson, MD, Ph.D. said in a talk in 2011.
Sadly, as a chiropractor’s patient with long-Covid and congestive heart failure related, “I tried umbilical cord stem cells. They didn’t work.” There were no live stem cells in the product with which he was treated or other commercially available perinatal vials, studies revealed:
Perinatal refers to just before or shortly after birth. Thus, perinatal stem cells come from birth tissues or fluids, i.e., umbilical cord blood and tissue, placental blood and tissue, and amniotic tissue and fluid.
Cells release tiny sacs or vesicles called exosomes. Like carrier pigeons, exosomes carry messages to nearby cells.
A doctor wanting to participate in the stem cell wild, wild west asked a lawyer specializing in stem cell regulatory affairs:
Contrary to the FDA’s warning letters, a NextHealth patient coordinator insisted that Vitti’s and Organicell’s products are FDA-approved and that the manufacturers certify all lots are contaminant-free. Where did she get that idea?
At the other end of the spectrum, 
“Of course, they work. We are all walking stem cell products – the sperm, and the egg.” James Willerson, MD, Ph.D. Dr. Willerson went on to publish Buying New Soul (2012). Here he hypothesized that adipose tissue was the best source of adult stem cells.
Sam era un dentista productivo, un golfista recreativo, un padre orgulloso y un marido feliz. Sin embargo, en 2013 su esposa Flo, médica jubilada, inició una audaz batalla de veinte años para revertir su demencia, enfermedad vascular y prediabetes. En abril de 2020, Sam sufrió un ictus y contrajo Covid y neumonía en el hospital. Permaneció allí dos meses.
Además, los griegos desarrollaron las primeras consideraciones científicas sobre la sangre. Ya en tiempos de Homero (8th o 9th A.C.), resumieron cuatro conceptos que siguen siendo válidos hoy en día:
En 1885, Rudolph Virchow acuñó el término "isquemia" para caracterizar la falta de flujo sanguíneo en un órgano o tejido. En palabras llanas, isquemia significa que la sangre no circula por los capilares, vasos sanguíneos, venas o arterias.
El largo declive de Sam
La historia de Sam personifica la complejidad de la mala salud relacionada con la edad:
Flo también sabía que debía evitar las combinaciones de fármacos, incluidos los antidepresivos, los antipsicóticos, los anticonvulsivos y los medicamentos para dormir (polifarmacia). Los neurólogos prescriben polifarmacia a los pacientes con enfermedades neurodegenerativas a pesar de su contribución bien documentada a la progresión y gravedad de la demencia. En otras palabras, las empresas farmacéuticas se benefician y los pacientes pagan el precio. 
Flo creía en el poder del cuerpo para curarse a sí mismo. Por eso se sintió atraída por el protocolo RECODE.
Flo solicitó documentos que respaldaran los posibles beneficios para la memoria de Sam.
Según la 
En consonancia con los estudios que Ambrose facilitó a Flo, las pruebas objetivas indican que la terapia celular redujo el riesgo de Sam de sufrir otra apoplejía catastrófica o un infarto de miocardio.
RJ jugó al béisbol, al fútbol, al snowboard y al golf durante su infancia.
"No aparecía nada en la resonancia magnética ni en las radiografías, pero no podía mover el brazo. Me sometí a una operación exploratoria. El cirujano descubrió que tenía el manguito de los rotadores y el labrum destrozados.
En este caso, el desgarro masivo del manguito de los rotadores (MRCT) de RJ causó incapacidad y dolor. Un MRCT precipita un Espiral de degeneración empezando por la inflamación, la respuesta inmunitaria anormal y la falta de riego sanguíneo. Esto conduce a la muerte celular programada (apoptosis), la cicatrización y la degeneración.
Más preocupante aún, RJ experimentó síntomas de desregulación multisistémica:
"Ya no me siento deprimida como antes. Soy optimista y tengo más energía. No me despierto empapado en sudor y ahora sólo necesito dormir unas ocho horas. Antes dormía de 12.00 a 14.00 y también hacía una siesta de una hora. Ahora entreno béisbol y fútbol 15 horas al día", informó RJ.
El cuidado de la columna vertebral tiene sus orígenes en la antigüedad. El papiro quirúrgico Edwin Smith, un documento egipcio escrito en el siglo XVII a.C., es el primer análisis conocido de las lesiones relacionadas con el cuello y la espalda. Hipócrates (siglo IV a.C.) experimentó con la tracción o presión local para corregir deformidades de la columna vertebral. Aristóteles también contribuyó a nuestra comprensión actual del cuello y la columna vertebral.
Pero aún quedaba más por descubrir que la FSU. Más recientemente, los investigadores empezaron a centrarse en la viciosa interacción entre lesiones traumáticas, desgaste, inflamación y otras enfermedades (comorbilidades). Por ejemplo, los pacientes con cardiopatías, diabetes, afecciones neurológicas y enfermedades autoinmunes tienen una mayor prevalencia de trastornos de la columna vertebral que los que no padecen esas afecciones. De hecho, Barb, Trish, Kathy y Jeff vivían con otras enfermedades crónicas debilitantes, como artritis, hipermovilidad, insuficiencia renal y lesión medular, respectivamente. 
A principios del siglo XVI, Leonardo da Vinci se interesó por la anatomía de los árboles. Su Regla de los árboles explicaba el equilibrio entre el tronco y las ramas de un árbol. Contó los anillos de los troncos de los árboles para determinar "la naturaleza de las estaciones pasadas".
Un arboricultor cultiva árboles; su eliminación es el último recurso. Lo primero que se les pasa por la cabeza es cómo salvar el árbol. Para hacer su trabajo, los arboricultores cultivan el árbol entero. Utilizan fertilizantes, riego y otras herramientas regenerativas para restaurar el tronco, las ramas y las hojas del árbol.
La medalla de oro olímpica de Muhammed Ali en 1960 inició su ascenso a "El Más Grande", pero los innumerables golpes que recibió en la cabeza para cansar a su oponente acabaron en una lucha fallida durante años por salvar su cerebro.
En 2000, Tim se retiró de la competición de lanchas motoras en alta mar con cuatro récords mundiales de velocidad. En una ocasión alcanzó más de 180 mph.
El temblor esencial es un trastorno del sistema nervioso (neurológico) que provoca temblores involuntarios y rítmicos. Puede afectar a casi cualquier parte del cuerpo, pero el temblor se produce con mayor frecuencia en las manos, sobre todo al realizar tareas sencillas, como beber de un vaso, escribir a mano o atarse los cordones de los zapatos.
"Debo de haber sufrido 1.000 conmociones cerebrales mientras corría. Probablemente perdí el conocimiento 100 veces al volante por las fuerzas G", calculó Tim.
Para solucionarlo, los médicos recetan a los pacientes fármacos para cada dolencia o síntoma, por ejemplo, Sinemet para el Parkinson, Ambien para dormir, esteroides para la artritis, opioides para el dolor, etc.
Los investigadores del John Hopkins desarrollaron una prueba de BDNF en sangre que podría haber predicho la gravedad del daño craneal de Ali y su evolución. Su estudio demostró que los pacientes con lesiones cerebrales tienen menos de un tercio del BDNF que los que tienen cerebros sanos.
Las ADRC también enriquecen el cerebro con factor de crecimiento endotelial vascular (VEGF). El VEGF restablece el flujo sanguíneo y reduce la inflamación en tejidos, vasos sanguíneos y órganos debilitados. Un estudio halló niveles más altos de VEGF en asintomático ancianos que murieron con placas amiloides en comparación con los pacientes sintomáticos de Alzheimer.
